ATOS (Atossa Therapeutics) Ending Cash Position: $31.83 Mil (As of Mar. 2026)


ATOS Atossa Therapeutics Inc ATOS
26 GF Score
Price $2.13
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Ending Cash Position?

Atossa Therapeutics ATOS +3.92% 26 Ending Cash Position is $31.83 Mil as of Mar. 2026. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Atossa Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $31.83 Mil.

Atossa Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($51.96 Mil) to Dec. 2025 ($41.41 Mil) and declined from Dec. 2025 ($41.41 Mil) to Mar. 2026 ($31.83 Mil).

Atossa Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($88.57 Mil) to Dec. 2024 ($71.19 Mil) and declined from Dec. 2024 ($71.19 Mil) to Dec. 2025 ($41.41 Mil).

Atossa Therapeutics Ending Cash Position Related Terms

Atossa Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Atossa Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics Ending Cash Position Chart

Atossa Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 136.49 111.00 88.57 71.19 41.41

Atossa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.23 57.97 51.96 41.41 31.83
ATOS
26GF Score
Atossa Therapeutics Inc ATOS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Atossa Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=71.194+-29.785
=41.41

Atossa Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=41.409+-9.581
=31.83

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $31.83 Mil mean?
Atossa Therapeutics (ATOS) has a Ending Cash Position of $31.83 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Atossa Therapeutics and its competitors.
Is Atossa Therapeutics' Ending Cash Position too high?
Atossa Therapeutics' current Ending Cash Position is $31.83 Mil. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' Ending Cash Position compare to QNCX and ZIVO?
Atossa Therapeutics' Ending Cash Position of $31.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Atossa Therapeutics and its competitors. Atossa Therapeutics's current Ending Cash Position is $31.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current Ending Cash Position of $31.83 Mil. The current Ending Cash Position is $31.83 Mil. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current Ending Cash Position is $31.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for ATOS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price